Avecho Biotechnology Limited (ASX:AVE)

Market Cap	47.76M +201.0%
Revenue (ttm)	1.24M +9.3%
Net Income	-4.42M
EPS	-0.00
Shares Out	3.67B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,984,069
Average Volume	7,589,765
Open	0.0120
Previous Close	0.0120
Day's Range	0.0120 - 0.0130
52-Week Range	0.0030 - 0.0130
Beta	1.18
RSI	68.94
Earnings Date	May 28, 2026

About Avecho Biotechnology

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVE

Financial Performance

In 2025, Avecho Biotechnology's revenue was 1.24 million, an increase of 9.28% compared to the previous year's 1.13 million. Losses were -4.42 million, 41.5% more than in 2024.